Available datapackage for study 'A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis'

To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for MS to get worse. Other objectives of the study are to determine the safety and tolerability of BG00012, as well as the effect it may have on tests and evaluations used to assess MS. Additionally, glatiramer acetate is being used to compare its benefits and risks with placebo and BG00012.

本研究旨在明确BG00012疗法能否在特定时段内降低多发性硬化（Multiple Sclerosis, MS）的复发次数。本研究的其他目标包括：探究随着时间推移，BG00012疗法是否能够减少MS患者常见的特定类型脑病变数量，并延缓MS病情恶化的进程。本研究的其他研究目标还包括明确BG00012的安全性与耐受性，以及其对用于评估MS的各类检测与评估手段可能产生的影响。此外，本研究还将醋酸格拉替雷（glatiramer acetate）与安慰剂（placebo）及BG00012进行获益与风险方面的对比。